Joint effects of substance use disorders and recent substance use on HIV viral non‐suppression among people engaged in HIV care in an urban clinic, 2014–2019
Catherine R. Lesko(Johns Hopkins University), Geetanjali Chander(Johns Hopkins University), Jarratt D. Pytell(Kaiser Permanente), Jeanne Keruly(Johns Hopkins University), Heidi E. Hutton(Johns Hopkins University), Oluwaseun Falade‐Nwulia(Johns Hopkins University), Richard D. Moore(Johns Hopkins University), Anthony T. Fojo(Johns Hopkins University)
Cited by 9
Related Papers
Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory Concentration
|The Journal of Infectious Diseases|1987|1.1k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694